Brabant Pharma

Brabant has licensed exclusive access to new clinical data utilising up to 20 years of case studies showing exceptional efficacy for the treatment in children with Dravet Syndrome which are frequently unresponsive to standard anticonvulsants.

Brabant is proposing a Dravet Syndrome Care Program, including a patient registry, which enables the careful monitoring of all children on treatment.

Brabant is working closely with Key Opinion Leaders and patient advocacy groups in the US, EU and globally.